Roche Holding AG (XTER:RHO) FFO


XTER:RHO Roche Holding AG XTER:RHO
79 GF Score
Price €373.20
GF Value €296.02
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Roche Holding AG FFO?

FFO (Funds from operations) only applies to REITs.

XTER:RHO
79GF Score
Roche Holding AG XTER:RHO
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Roche Holding AG (XTER:RHO) Overvalued in 2026?

Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued. The current stock price of €373.20 is trading 26.1% above its estimated GF Value™ of €296.02. GuruFocus considers Roche Holding AG to be Modestly Overvalued.

Key valuation signals for XTER:RHO:

  • FFO:
  • GF Value™: €296.02 vs. price of €373.20 (26.1% above fair value)
  • GF Score™: 79/100 with 3 warning signs

No single metric tells the full story. See the XTER:RHO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Roche Holding AG Business Description

Address Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
79GF Score

Get the complete analysis for XTER:RHO

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€373.20
Price
€296.02
GF Value